- Home
- XERS vs TRML Comparison
XERS vs TRML Comparison
Compare XERS & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- TRML
- Stock Information
- Founded
- XERS 2005
- TRML 2021
- Country
- XERS United States
- TRML United States
- Employees
- XERS N/A
- TRML N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- TRML Health Care
- Exchange
- XERS Nasdaq
- TRML Nasdaq
- Market Cap
- XERS 526.3M
- TRML 509.8M
- IPO Year
- XERS 2018
- TRML N/A
- Fundamental
- Price
- XERS $4.24
- TRML $14.38
- Analyst Decision
- XERS Strong Buy
- TRML Strong Buy
- Analyst Count
- XERS 4
- TRML 8
- Target Price
- XERS $5.75
- TRML $52.86
- AVG Volume (30 Days)
- XERS 2.4M
- TRML 286.2K
- Earning Date
- XERS 03-06-2025
- TRML 03-18-2025
- Dividend Yield
- XERS N/A
- TRML N/A
- EPS Growth
- XERS N/A
- TRML N/A
- EPS
- XERS N/A
- TRML N/A
- Revenue
- XERS $203,070,000.00
- TRML N/A
- Revenue This Year
- XERS $20.47
- TRML N/A
- Revenue Next Year
- XERS $19.35
- TRML N/A
- P/E Ratio
- XERS N/A
- TRML N/A
- Revenue Growth
- XERS 23.89
- TRML N/A
- 52 Week Low
- XERS $1.69
- TRML $11.87
- 52 Week High
- XERS $4.50
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- TRML 51.34
- Support Level
- XERS $3.59
- TRML $11.92
- Resistance Level
- XERS $4.50
- TRML $13.28
- Average True Range (ATR)
- XERS 0.25
- TRML 0.90
- MACD
- XERS 0.03
- TRML 0.41
- Stochastic Oscillator
- XERS 72.34
- TRML 66.23
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.